Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0Z3CC
|
||||
| Former ID |
DNC007252
|
||||
| Drug Name |
2-morpholino-6-(quinolin-8-yl)-4H-pyran-4-one
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C18H16N2O3
|
||||
| Canonical SMILES |
C1COCCN1C2=CC(=O)C=C(O2)C3=CC=CC4=C3N=CC=C4
|
||||
| InChI |
1S/C18H16N2O3/c21-14-11-16(23-17(12-14)20-7-9-22-10-8-20)15-5-1-3-13-4-2-6-19-18(13)15/h1-6,11-12H,7-10H2
|
||||
| InChIKey |
GJFZIARIYRYNDJ-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | DNA-dependent protein kinase catalytic subunit | Target Info | Inhibitor | [1] | |
| KEGG Pathway | Non-homologous end-joining | ||||
| Cell cycle | |||||
| NetPath Pathway | IL1 Signaling Pathway | ||||
| Pathway Interaction Database | DNA-PK pathway in nonhomologous end joining | ||||
| Coregulation of Androgen receptor activity | |||||
| Class I PI3K signaling events mediated by Akt | |||||
| BARD1 signaling events | |||||
| Reactome | Nonhomologous End-Joining (NHEJ) | ||||
| WikiPathways | DNA Damage Response | ||||
| Non-homologous end joining | |||||
| FAS pathway and Stress induction of HSP regulation | |||||
| Cytosolic sensors of pathogen-associated DNA | |||||
| Retinoblastoma (RB) in Cancer | |||||
| Prostate Cancer | |||||
| Double-Strand Break Repair | |||||
| Cell Cycle | |||||
| miRNA Regulation of DNA Damage Response | |||||
| References | |||||
| REF 1 | J Med Chem. 2007 Apr 19;50(8):1958-72. Epub 2007 Mar 20.Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependent protein kinase inhibition, and identification of the first potent and selective inhibitor of the ataxia telangiectasia mutated kinase. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.